Herein, we investigated the synergism of PSPC1 inhibition in combination with olaparib in a preclinical model with PSPC1-expressing, BRCA1/2-mutated breast and ovarian cancer, demonstrating the synergistic anticancer activity of the combination. The gene discussed is BRCA1; the disease is ovarian cancer.